Steve Krognes, serving as a director at Guardant Health, Inc. (NASDAQ: GH), completed a transaction involving the sale of 9,294 shares of the company's common stock on June 4, 2026. The aggregate value of this divestment reached $1,231,521. The execution of these shares occurred within a specific price band, ranging from $132.50 to $132.71. The weighted average price for the transaction was calculated at $132.5072. Following the completion of this sale, Krognes maintains a direct ownership position of 10,222 shares of Guardant Health common stock. This insider activity was formally disclosed through a recent Form 4 filing submitted to the Securities and Exchange Commission.
The timing of this executive sale coincides with Guardant Health shares trading in close proximity to their 52-week high of $134.28. The stock has demonstrated remarkable appreciation, recording a 159% gain over the trailing twelve-month period. This performance has contributed to a current market capitalization of $16.68 billion. Valuation analysis provided by InvestingPro indicates that the stock may be trading at levels considered overvalued relative to calculated fair value metrics. Investors seeking further insights can access additional ProTips and comprehensive analysis through the platform’s detailed Pro Research Report.
Guardant Health has recently attracted considerable attention from the analyst community following significant operational developments. A primary catalyst for this attention is the early FDA approval received for the G360 Liquid CDx test. This regulatory milestone has prompted several analyst firms to adjust their coverage and price targets.
BTIG responded to this regulatory achievement by raising its price target to $155, while maintaining a Buy rating on the stock. TD Cowen also reiterated its Buy rating, setting a price target of $127. TD Cowen specifically emphasized the unexpected timing of the FDA approval as a key factor in their assessment.
Goldman Sachs initiated coverage on Guardant Health with a Buy rating and established a price target of $165. Their analysis highlights growth drivers including the FDA-approved G360 CDx 740-gene panel and upcoming product launches. Wolfe Research began coverage with an outperform rating and a price target of $150, noting the expanding growth of the company’s oncology tests. Stifel maintained its Buy rating, setting a price target of $130, based on positive feedback from experts in colorectal cancer screening and the potential for improved coverage.
These collective analyst actions underscore a positive outlook surrounding Guardant Health’s recent achievements and future potential. The company's stock closed at $125.61, reflecting a decline of $7.45 or 5.60%. After-hours trading showed further movement, with the stock closing at $125.04, down $0.57 or 0.45%. The intersection of executive selling, strong stock performance, and analyst upgrades presents a complex picture for investors monitoring the precision medicine and oncology testing sectors.